Psilocybin

Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer

Retrieved on: 
Monday, November 6, 2023
Niacin, MADRS, Principal investigator, MDD, Sunstone, Medicine, Psilocybin, JAMA Oncology, Oncology, Safety, Depression, Cancer, Pain, Patient, Pharmaceutical industry

Study participants are adults with cancer and major depressive disorder (MDD) who are receiving up to two doses of psilocybin with concurrent therapy.

Key Points: 
  • Study participants are adults with cancer and major depressive disorder (MDD) who are receiving up to two doses of psilocybin with concurrent therapy.
  • Sunstone aims to recruit 56 patients into this single-center study to explore the efficacy, safety, and tolerability of up to two 25-mg doses of psilocybin administered at an interval of 9 to 10 weeks (ClinicalTrials.gov ID NCT05947383).
  • This new study includes a placebo control arm, the use of group administration, and - for the first time - multiple doses.
  • We look forward to making a further contribution to the clinical development of this potentially vitally important treatment modality.”

Oakland activists file statewide ballot initiative seeking safe and legal access to psychedelics for medical and therapeutic uses

Retrieved on: 
Saturday, October 28, 2023
Alternative Medicine, Public Policy, Government, Cannabis, State, Local, Health, Advocacy Group Opinion, Natural Resources, Psilocybin, Post-traumatic stress disorder, Mescaline, Sale, MDMA, Hodges, Johns Hopkins, Quality control, PTSD, Traumatic brain injury, Suicide, DMT, Psychedelic drug, Language, Depression, Anxiety, Tic disorder, Addiction, Mental health, Senate, Nursing

Dave Hodges, proponent of safe access to psychedelics for medical, therapeutic and spiritual use, today submitted the Psychedelic Wellness & Healing Initiative to the California Attorney General’s office for the 2024 ballot.

Key Points: 
  • Dave Hodges, proponent of safe access to psychedelics for medical, therapeutic and spiritual use, today submitted the Psychedelic Wellness & Healing Initiative to the California Attorney General’s office for the 2024 ballot.
  • If it wins passage, the initiative will allow for the sale, possession and use of psychedelics including Psilocybin, MDMA, DMT, and Mescaline for medical and therapeutic purposes.
  • Hodges, founder of the Oakland-based Church of Ambrosia , said the initiative will need 546,651 valid signatures to qualify for the 2024 ballot.
  • The initiative also would create a statewide framework for regulating possession, use, cultivation and production of substances for medical and therapeutic use.

Mydecine Provides Q4 2023 Business Update

Retrieved on: 
Thursday, October 26, 2023
Psilocybin, Government, FDA, MDMA, CAD, Half-life, University, MAPS, Canadian government scientific research organizations, Invention, OTC, Research, CSE, Drug development, University of Alberta Faculty of Extension, PTSD, University of Alberta, Drug discovery, Partnership, Probability, API, Ōtsuka, Safety, Burn, AI, MYIG, Patient, Mental health, Pharmaceutical industry

The Company has spent the past few months diligently working to simplify its business model, streamline workflow and processes, and reduce burn rate while increasing output and efficiencies in order to ensure the Company's future success.

Key Points: 
  • The Company has spent the past few months diligently working to simplify its business model, streamline workflow and processes, and reduce burn rate while increasing output and efficiencies in order to ensure the Company's future success.
  • Through this process, the Company has made a number of strategic decisions that it believes will substantially benefit shareholders and increase the probability of long-term success.
  • The University of Alberta consistently rates in the top five in the world for AI drug development.
  • Through adversity, Mydecine has become a more robust, well-managed, streamlined, efficient, and productive organization with a high likelihood of success.

Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs

Retrieved on: 
Thursday, October 26, 2023
Alternative Medicine, Mental Health, Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Patent, NYSE, IV, DSM-IV codes, Psilocybin, Inc., European Patent Office, DMT, NEO, European Patent Convention, Patient, Pharmaceutical industry

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that the European Patent Office (“EP”) has granted a patent protecting Cybin’s proprietary deuterated psilocybin analog and N, N-dimethyltryptamine (“DMT”) programs.

Key Points: 
  • Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that the European Patent Office (“EP”) has granted a patent protecting Cybin’s proprietary deuterated psilocybin analog and N, N-dimethyltryptamine (“DMT”) programs.
  • 4,031,529 provides composition of matter protection for certain deuterated tryptamine compounds, including deuterated psilocybin analogs within the CYB003 program and deuterated analogs of DMT within Cybin’s DMT program, as well as their medical use.
  • “Following quickly on from the two recently announced U.S. patents granted in respect of our deuterated DMT program, this European patent further strengthens our intellectual property protection around our deuterated DMT and deuterated psilocybin programs.
  • The Company expects to report topline data from its deuterated psilocybin and DMT programs in the fourth quarter of 2023.

Pioneers and Innovators in Psilocybin Treatments and How Big Pharma Wants in on the Game

Retrieved on: 
Thursday, October 19, 2023
Post-traumatic stress disorder, Big Pharma, FDA, CAD, KAYS, Patent, Food, Oregon Health Authority, Therapy, Sacredness, COMPASS, DSM-IV codes, News, Pharma, FDT, US Foods, Research, Initial, OTCQB, Psilocybin, Yoga, Breakthrough therapy, Private placement, Good, Ōtsuka, Eating, Anorexia nervosa, Depression, OHA, Medication, Anxiety, Investment, Patient, Neuropsychiatry, TRD, Pulse, Mental health, Pharmaceutical industry, Nursing

As psilocybin and other alternative health innovators try to shape the future of mental health, Pharma and traditional healthcare investors are watching and waiting to get their share.

Key Points: 
  • As psilocybin and other alternative health innovators try to shape the future of mental health, Pharma and traditional healthcare investors are watching and waiting to get their share.
  • (OTCQB: KAYS) is the only U.S. public company engaged in securing an Oregon Health Authority ("OHA") license to open a psilocybin treatment center.
  • Kaya Holdings just announced that it has closed an additional round of bridge financing targeted to complete KAYS' planned psilocybin treatment center in Portland, Oregon.
  • Reporting on the Mindset Pharma deal, Psychedelicspotlight.com said , "Big Pharma has certainly taken note of the potential therapeutic benefits of psychedelics.

Brain & Behavior Research Foundation Awards $10.2 Million in Young Investigator Grants to 150 Mental Health Scientists

Retrieved on: 
Thursday, October 19, 2023
Brain & Behavior Research Foundation, Spectrum, Psychiatry, Psychosis, TFU, Prevalence, Pathology, Bipolar disorder, Research, Brain, OCD, PTSD, Psilocybin, Borderline personality disorder, Schizophrenia, Eating, M.D, Depression, Anxiety, Presidential Young Investigator Award, DSM-IV codes, ADHD, B cell, Pharmaceutical industry, Medical imaging, Young

A third grantee will study the application of transcranial focused ultrasound (tFUS) in such illnesses as PTSD, anxiety, and OCD.

Key Points: 
  • A third grantee will study the application of transcranial focused ultrasound (tFUS) in such illnesses as PTSD, anxiety, and OCD.
  • “BBRF Young Investigators represent a new generation of researchers who are pioneering breakthroughs in mental health research.
  • They are at the cutting edge of progress in brain and psychiatric research,” said Jeffrey Borenstein, M.D, President & CEO of the Brain & Behavior Research Foundation.
  • “BBRF Young Investigator grants have led to groundbreaking research that has improved the lives of people living with mental illness,” said Herbert Pardes, M.D., President of the BBRF Scientific Council.

Orange Photonics Unveils LightLab 3 Psy Analyzer, Revolutionizing Analytical Testing for Psychedelic Mushrooms and Infused Products

Retrieved on: 
Thursday, October 19, 2023
Laboratory, Federal, FDA, Psilocybin, State, University, HPLC, Research, High-performance liquid chromatography, Medical device, Pharmaceutical industry

NEW LONDON, N.H., Oct. 19, 2023 /PRNewswire/ -- Orange Photonics, a pioneer in analytical testing solutions, is pleased to introduce LightLab 3 Psy Analyzer, which allows non-technical users to measure psilocybin, psilocin, and ACO-DMT in psychedelic mushrooms and infused products.

Key Points: 
  • NEW LONDON, N.H., Oct. 19, 2023 /PRNewswire/ -- Orange Photonics, a pioneer in analytical testing solutions, is pleased to introduce LightLab 3 Psy Analyzer, which allows non-technical users to measure psilocybin, psilocin, and ACO-DMT in psychedelic mushrooms and infused products.
  • LightLab 3 Psy Analyzer is an essential on-site testing tool for licensed operators and research institutions.
  • LightLab 3 Psy Analyzer quantifies the amount of psilocybin, psilocin, and ACO-DMT in psychedelic mushrooms, extracts and infused products.
  • For more information about the LightLab 3 Psy Analyzer and Orange Photonics' suite of analytical testing solutions, please visit www.orangephotonics.com .

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK

Retrieved on: 
Thursday, October 12, 2023
Psilocybin, University, MAR, OTC, European Union (Withdrawal) Act 2018, Health care, Investigational New Drug, CDI, Interest, MDMA, PTSD, Indian stock exchange, Novel, Biotechnology, Half-life, Financial Conduct Authority, CREST, Mental health, Issuer, Admission, FSE, PCT, Access, ISIN, NEO, Patent Cooperation Treaty, MYIG, Pharmaceutical industry, Security (finance), EU

Mydecine Innovations Group Inc. is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.

Key Points: 
  • Mydecine Innovations Group Inc. is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.
  • The Companies various families of Novel 2nd generation molecules are showing significant improvements over the first generation of psychedelic treatments.
  • Josh Bartch, CEO of the Company stated, “We are incredibly excited to list our securities for trading in the UK on the AQSE Growth Market.
  • This announcement, together with any documents incorporated by reference, shall be deemed to constitute an admission document for the purposes of the AQSE Growth Market Rules for Issuers – Access.

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings

Retrieved on: 
Tuesday, October 10, 2023
Psilocybin, University, MAR, OTC, European Union (Withdrawal) Act 2018, Health care, Investigational New Drug, CDI, Interest, MDMA, PTSD, Indian stock exchange, Novel, Half-life, Financial Conduct Authority, CREST, Mental health, Issuer, Admission, CSE, PCT, Access, ISIN, Patent Cooperation Treaty, MYIG, Pharmaceutical industry, Security (finance), EU

Mydecine Innovations Group Inc. is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.

Key Points: 
  • Mydecine Innovations Group Inc. is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.
  • The Companies various families of Novel 2nd generation molecules are showing significant improvements over the first generation of psychedelic treatments.
  • Josh Bartch, CEO of the Company stated, “We are incredibly excited to list our securities for trading in the UK on the AQSE Growth Market.
  • This announcement, together with any documents incorporated by reference, shall be deemed to constitute an admission document for the purposes of the AQSE Growth Market Rules for Issuers – Access.

PurMinds(TM) NeuroPharma Awarded Synthetic Psilocybin API Import Permit from Health Canada to Develop GMP-Compliant Psychedelic Drug Product Formulations for Clinical Trial Supply

Retrieved on: 
Wednesday, October 11, 2023
Psilocybin, General counsel, MDMA, Prohibition of drugs, Ground substance, Safety, Export and Imports Permits Act, FDA, GMP, Growth, Clinical trial, License, API, The Company, International, Pharmaceutical industry

PurMinds™ Dealer's License authorizes the production, formulation and global supply of psychedelic compounds, and the Company's newly awarded Import Permit allows for the legal importation of synthetic psilocybin active pharmaceutical ingredient (API) from PurMinds™ US-based API supplier to its Ontario-based neurolab and production facility.

Key Points: 
  • PurMinds™ Dealer's License authorizes the production, formulation and global supply of psychedelic compounds, and the Company's newly awarded Import Permit allows for the legal importation of synthetic psilocybin active pharmaceutical ingredient (API) from PurMinds™ US-based API supplier to its Ontario-based neurolab and production facility.
  • With MDMA therapy inching closer to receiving FDA approval, Alberta's regulation of psychedelic drugs for therapeutic use, and Australia's drug policy reform to reschedule MDMA and psilocybin, PurMinds™ anticipates a surge in the demand for investigatory psychedelic drug sales.
  • "These pivotal legislative reforms present a large growth opportunity for the Company that should greatly accelerate the pathway to positive cash flow," said Robin Shugar, J.D., Chief Commercial Officer and General Counsel.
  • "As one of the very few, licensed psychedelic mushroom cultivation and investigational drug product production facilities worldwide, and with a strong focus on safety, efficacy, and accessibility, PurMinds is ideally positioned to be at the forefront of clinical trial psychedelic drug product supply."